Wouter T Zandee1, Richard A Feelders1, Daan A Smit Duijzentkunst2, Johannes Hofland1, R Mick Metselaar3, Rogier A Oldenburg4, Anne van Linge3, Boen L R Kam2, Jaap J M Teunissen2, Esther Korpershoek5, Johanna M Hendriks6, Huda Abusaris7, Cleo Slagter7, Gaston J H Franssen6, Tessa Brabander2, Wouter W De Herder1. 1. Department of Internal Medicine, Sector Endocrinology. 2. Department of Radiology & Nuclear Medicine, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands. 3. Department of ENT Surgery, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands. 4. Department of Clinical Genetics, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands. 5. Department of Pathology, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands. 6. Department of Surgery, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands. 7. Department of Radiation Oncology, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Abstract
OBJECTIVES: Inoperable or metastatic paragangliomas (PGLs) and malignant pheochromocytomas (PCCs) are rare tumours with limited options for systemic treatment. Aim of this study was to assess the safety and efficacy of the radiolabelled somatostatin analogue (177LutetiumDOTA0-Tyr3)octreotate (177Lu-DOTATATE) for the treatment of PGLs and PCCs. METHODS: Patients with histologically proven inoperable or malignant PGLs and PCCs treated with 177Lu-DOTATATE at our centre were retrospectively analysed. Patients were treated with up to four cycles of 177Lu-DOTATATE with an intended dose of 7.4 Gb per cycle. Response was assessed with use of RECIST 1.1. RESULTS: Thirty patients were included: 17 with parasympathetic, 10 with sympathetic PGLs and 3 with PCCs. Grade 3/4 subacute haematotoxicity occurred in 6 (20%) of patients. A reversible subacute adverse event due to cardiac failure following possible catecholamine release occurred in two patients. Best tumour response was partial response in 7 (23%) and stable disease in 20 (67%), whereas 3 (10%) patients had progressive disease. In 20 patients with baseline disease progression, tumour control was observed in 17 (85%); the median progression-free survival was 91 months in patients with parasympathetic PGLs, 13 months in patients with sympathetic PGLs and 10 months in patients with metastatic PCCs. CONCLUSION: This study suggests that PRRT with 177Lu-DOTATATE is a safe and effective treatment option for patients with inoperable or malignant PGL and PCC.
OBJECTIVES: Inoperable or metastatic paragangliomas (PGLs) and malignant pheochromocytomas (PCCs) are rare tumours with limited options for systemic treatment. Aim of this study was to assess the safety and efficacy of the radiolabelled somatostatin analogue (177LutetiumDOTA0-Tyr3)octreotate (177Lu-DOTATATE) for the treatment of PGLs and PCCs. METHODS: Patients with histologically proven inoperable or malignant PGLs and PCCs treated with 177Lu-DOTATATE at our centre were retrospectively analysed. Patients were treated with up to four cycles of 177Lu-DOTATATE with an intended dose of 7.4 Gb per cycle. Response was assessed with use of RECIST 1.1. RESULTS: Thirty patients were included: 17 with parasympathetic, 10 with sympathetic PGLs and 3 with PCCs. Grade 3/4 subacute haematotoxicity occurred in 6 (20%) of patients. A reversible subacute adverse event due to cardiac failure following possible catecholamine release occurred in two patients. Best tumour response was partial response in 7 (23%) and stable disease in 20 (67%), whereas 3 (10%) patients had progressive disease. In 20 patients with baseline disease progression, tumour control was observed in 17 (85%); the median progression-free survival was 91 months in patients with parasympathetic PGLs, 13 months in patients with sympathetic PGLs and 10 months in patients with metastatic PCCs. CONCLUSION: This study suggests that PRRT with 177Lu-DOTATATE is a safe and effective treatment option for patients with inoperable or malignant PGL and PCC.
Authors: Edward P Lin; Bennett B Chin; Lauren Fishbein; Toshio Moritani; Simone P Montoya; Shehanaz Ellika; Shawn Newlands Journal: Radiol Imaging Cancer Date: 2022-05
Authors: Camilo Jimenez; Guofan Xu; Jeena Varghese; Paul H Graham; Matthew T Campbell; Yang Lu Journal: Curr Oncol Rep Date: 2022-01-21 Impact factor: 5.075
Authors: Jorge A Carrasquillo; Clara C Chen; Abhishek Jha; Karel Pacak; Daniel A Pryma; Frank I Lin Journal: J Nucl Med Date: 2021-09-01 Impact factor: 10.057
Authors: S Severi; A Bongiovanni; M Ferrara; S Nicolini; F Di Mauro; M Sansovini; I Lolli; E Tardelli; C Cittanti; V Di Iorio; E Mezzenga; E Scarpi; T Ibrahim; G Paganelli; S Zovato Journal: ESMO Open Date: 2021-06-14
Authors: Neeta Pandit-Taskar; Karel Pacak; Abhishek Jha; David Taïeb; Jorge A Carrasquillo; Daniel A Pryma; Mayank Patel; Corina Millo; Wouter W de Herder; Jaydira Del Rivero; Joakim Crona; Barry L Shulkin; Irene Virgolini; Alice P Chen; Bhagwant R Mittal; Sandip Basu; Joseph S Dillon; Thomas A Hope; Carina Mari Aparici; Andrei H Iagaru; Rodney J Hicks; Anca M Avram; Jonathan R Strosberg; Ali Cahid Civelek; Frank I Lin Journal: Clin Cancer Res Date: 2021-03-08 Impact factor: 13.801